Never Give Up: lesson learned from a severe COVID-19 patient. by Tonelli, Roberto et al.
ARTICLE IN PRESS+ModelPULMOE-1478; No. of Pages 4
Pulmonol. 2020;xxx(xx):xxx--xxx
www.journalpulmonology.org
LETTER TO THE EDITOR
Never Give Up: Lesson learned from
a  severe COVID-19 patient
SARS-CoV2  pneumonia  at  our  University  Hospital  in  Mod-
ena  on  last  March  5th.  A  multidisciplinary  medical  staffTo  the  Editor,
COVID-19  pandemic  is  causing  major  health  consequences
in  affected  persons  needing  hospital  admission.  Since  the
first  epidemic  outbreak  in  China  we  have  learned  that
several  factors  including  older  age,  comorbidities  and  indi-
vidual  immunological  responses  to  infection  may  differently
address  the  risk  of  disease  progression  and  outcome.1
Moreover,  there  is  now  quite  a  unanimous  consensus  that
mortality  rate  of  critically  ill  patients  with  SARS-CoV2
pneumonia  admitted  to  Intensive  Care  Unit  (ICU)  is  really
considerable2 and  even  a  slightly  higher  than  that  recorded
in  patients  with  moderate  to  severe  Acute  Respiratory  Dis-
tress  Syndrome  (ARDS).3
Different  attempts  using  experimental  anti-viral4 and/or
systemic  anti-inflammatory  drugs5,6 have  been  made  to
counteract  both  disease  progression  and  fatal  progno-
sis.  Meanwhile,  an  expert  opinion-based  document  was
launched  in  order  to  address  the  early  management-related
actions  for  the  individual  patient,  including  the  choice  of  an
appropriate  setting  of  care  and  the  timing  for  non-invasive
(NIV)  or  invasive  mechanical  ventilation  (MV).7
In  light  of  this,  we  here  report  the  clinical  course
of  a  72-year  old  Caucasian  male  (M.A.)  admitted  for
composed  of  different  specialists  (infectious  diseases,  pul-
monology,  intensive  care)  was  in  charge  of  care  and  assuming
shared  clinical  decisions.
Past  medical  history  was  characterized  by  limited
atherosclerosis,  systemic  arterial  hypertension,  and  stable
chronic  B-cell  lymphocytic  leukemia  (LLC)  only  requiring
periodic  follow-up.  Onset  of  symptoms  was  reported  6  days
before  admission  and  infection  by  SARS-CoV-2  was  con-
firmed  by  RT-PCR  swab  nasal/throat  samples  on  the  day  of
admission.  Patient  presented  with  fever  (38 ◦C),  dry  cough,
tachypnea  (respiratory  rate-RR  =  24  bpm)  and  mild  respira-
tory  failure  (PaO2/FiO2  242  breathing  room  air).  Fig.  1 shows
the  chest-X-ray  and  the  lung  ultrasound  pattern  on  admission
(day  1).  Given  the  neurological  and  hemodynamic  stability
(Subsequent  Organ  Failure  Assessment-SOFA  score  was  1)  he
was  admitted  to  the  Infectious  Disease  Unit  where  oxygen
supply  through  nasal  cannula  at  the  flow  of  2  L/min  and
antiviral  therapy  with  darunavir/cobicistat  was  started  in
addition  to  hydroxychloroquine  and  azithromycin  according
to  our  local  recommendations.  Blood  C-reactive  Protein  (CRP
7.8  mg/dl)  was  high  whereas  white  blood  cell-WBC  count
(62.510  ml--1)  was  abnormally  increased  also  due  to  his  LLC
condition.
On  day  4,  patient  experienced  a  major  respiratory  wors-
ening  (PaO2/FiO2  105),  with  RR  >  40  bpm)  despite  oxygenPlease  cite  this  article  in  press  as:  Tonelli  R,  et  al.  Never  G
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Figure  1  Chest  X-ray  on  admission  shows  diffuse  interstitial  abnorm
the local  ultrasound  patterns,  in  particular:  irregular  vertical  artifact
consolidations in  the  upper  anterior  sites  and  thick  and  confluent  B  
https://doi.org/10.1016/j.pulmoe.2020.04.012
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alities  alongside  scattered  bilateral  infiltrates.  Arrows  indicate
s  (B-lines)  with  impaired  pleural  sliding  next  to  subpleural  small
lines  in  the  low  posterior  site.
Elsevier Espan˜a, S.L.U. This is an open access article under the CC
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oigure  2  Time  course  of  the  inflammatory  serum  biomarke
dmission in  the  COVID-19  area  at  the  University  Hospital  of  Mo
upply  at  FiO2  60%).  A  multidisciplinary  staff  evaluation  was
onducted  to  balance  the  need  for  immediate  endotracheal
ntubation  (ETI)  and  MV  with  the  potential  risks  derived
rom  his  hematological  co-morbidity.  Decision  was  taken
or  a  non-ICU  care  approach  thus  NIV  in  pressure  support
ode  was  started  with  the  aim  to  target  a  pulse  oximetry
evel  >90%  and  a  RR  <30  bpm.  At  the  same  time,  other  anti-
nflammatory  drugs  for  off-label  therapeutic  indication  were
ot  available  in  the  hospital  pharmacy.
From  day  5  to  9,  patient  continued  on  supported  breath-
ng.  Finally,  he  presented  uncontrollable  respiratory  distress
espite  NIV  and  maximal  oxygen  supply  (PaO2/FiO2  <  100)
n  day  10.  There  was  a  further  multidisciplinary  evalua-
ion  and,  having  become  available,  off-label  i.v.  Tocilizumab
8  mg/kg  of  body  weight  with  2  infusions  12-hour  apart)6
nd  admission  to  ICU  for  endo-tracheal  intubation  and
echanical  ventilation  were  adopted  as  rescue  thera-
ies.  On  day  13  patient’s  condition  and  gas  exchange
mproved  (PaO2/FiO2  121)  and  tracheostomy  was  per-
ormed,  while  patient  progressively  returned  to  an  assisted
reathing  modality.  The  time  course  of  the  main  inflam-
atory  serum  markers  over  the  admission  period  is  shown
n  Fig.  2.
On  March  18th  (day  15),  M.A.  was  transferred  to  a  differ-
nt  hospital  in  our  provincial  area  (Ospedale  di  Sassuolo)
or  weaning  purpose.  Respiratory  condition  progressively
mproved  reaching  spontaneous  breathing  on  day  23,  while
 supervised  physiotherapy  protocol  was  started  due  to
he  consequences  of  prolonged  immobility.  Tests  to  assess
he  vocal  cord  and  swallow  integrity  were  then  performed,
ccording  to  the  recommended  procedures,  leading  on  April
th  (day  31)  to  removal  of  both  the  naso-gastric  tube  and
he  tracheal  cannula.  Oxygen  supplementation  was  alsoPlease  cite  this  article  in  press  as:  Tonelli  R,  et  al.  Never  G
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ithdrawn  on  the  same  day.  Two  consecutive  nasal/throat
T-PCR  swab  samples  were  confirmed  negative  for  RNA  virus
nd  specific  immunoglobulin-G  were  dosed  in  serum,  so
o
n
edimer  (circle),  CRP  (square),  and  Platelets  (triangle),  during
.
atient  was  discharge  as  cured  and  transferred  to  a  reha-
ilitation  unit  to  complete  his  recovery  (day  33).
The  story  of  M.A.  confirms  the  heavy  risk  and  the  long  and
ifficult  clinical  process  behind  any  severe  pneumonia  due
o  SARS-CoV2  infection  and  prompts  several  considerations.
First,  it  is  quite  clear  that  the  clinical  course  in  patients
ospitalized  due  to  pneumonia  and  worsening  respiratory
ailure  is  unforeseeable,  thus  requiring  great  attention  and
rompt  action.  The  complexity,  comorbid  status  and  age  of
he  patient  only  partially  explain  this  variability.  Indeed,  it
as  been  recently  hypothesized  that  least  3  different  grades
f  increasing  severity  may  be  recognized,  which  correspond
o,  distinct  clinical  findings,  response  to  therapy  and  clinical
utcome,  and  are  likely  to  depend  on  the  balance  between
he  viral  phase  and  the  host  inflammatory  response.8
Second,  the  history  of  M.A.  at  least  partially  proposes  the
nprecedented  decisions  to  be  taken,  whether  by  hospital,
hysicians  and/or  nurses,  i.e.  withhold  a  ventilator  and/or
ccess  to  ICU  when  faced  with  an  anticipated  shortage  of
entilators  and  ICU-beds  during  an  uncontrolled  epidemic
utbreak9 or  with  a  clinical  discussion  on  a  proportionate
reatment.  This  might  in  turn  overexpose  clinicians  to  the
isk  of  civil  or  criminal  liability  in  the  absence  of  clear
overnment  assurance  when  facing  extraordinary  events.10
iven  the  particular  condition  to  which  M.A.  rushed  after
dmission,  the  decision  taken  to  proportion  intensity  of
espiratory  support  by  NIV  could  have  led  to  an  unwanted
iability.
Third,  it  should  be  noted  that,  as  tocilizumab  was
ot  available  to  prompt  a  potentially  anti-inflammatory
rug  effect,  even  in  a  later  stage  as  was  the  case  of  our
atient  (see  Fig.  2),  the  choice  to  use  NIV  was  indeed  the
nly  means  to  ‘‘buy  time’’  before  any  upgraded  decisionive  Up:  Lesson  learned  from  a  severe  COVID-19  patient.
2
f  care  could  be  taken.  This  highlights  the  role  that
oninvasive  respiratory  support  may  have  during  COVID-19
pidemic,  which  is  not  only  to  manage  the  advanced  hypoxic
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respiratory  failure,7 but  also  to  help  clinicians  to  assist  a
very  severely  ill  patient  even  if  at  high  risk.  Ongoing  data
on  this  epidemic  are  showing  that  the  decision  to  prevent
endotracheal  intubation  by  NIV  might  be  a  safe  option  for
patients.  While  we  are  waiting  for  more  convincing  data  on
the  role  of  anti-inflammatory  agents  to  early  brake  systemic
inflammation  and  progression  of  the  disease,6,11 it  has  been
discussed  whether  or  not  early  ETI  and  MV  would  be  the
best  option  for  the  COVID-19  patient’s  outcome.12 One  of
the  hypotheses  behind  this  is  that  COVID-19  is  not  a  typical
ARDS,  so  MV  in  many  cases  is  not  the  right  treatment.
COVID-19  patients  show  significant  vasoconstriction  of  small
blood  vessels  compared  to  the  healthy  and  ARDS  patients.
It  is  known  that  ventilation  reduces  the  small  blood  vessel
size,  meaning  it  is  probably  making  things  worse  for  most
COVID-19  patients.  Notably,  a  very  recent  audit  in  UK
in  over  6000  patients  shows  that  death  rate  in  COVID-19
patients  using  advanced  respiratory  support  (ETI,  MV,  ECMO)
is  significantly  higher  as  compared  with  patients  on  basic
support  (oxygen  with  inspiratory  fraction  >50%,  CPAP/BIPAP)
(66.3  vs.  51.6%,  respectively).  This  in  turn  expresses  a  much
higher  risk  rate  when  compared  to  that  (22%)  occurring
in  a  retrospective  series  of  hospitalized  non-COVID  viral
pneumonia.13
Finally,  present  experience  has  led  clinicians  to  the
evidence  that  such  a  very  severe  situation  with  difficult
and  risky  decisions  unavoidably  lead  the  patient  to  a  long
clinical  course  with  associated  disability.14 Since  beating
the  virus  is  just  the  beginning,  any  lack  of  access  to
early  physiotherapy  and  to  a  long-term  strategy  for  sur-
vivors  of  severe  COVID-19  is  a  problem  to  be  overcome
urgently.15
From  our  personal  experience  during  COVID-19  epidemic
we  encourage  colleagues  not  to  give  up  in  all  circumstances
due  to  this  happily  ending  story.
(At  the  time  of  submission,  the  smiling  photo  of  M.A.
received  1.641  like  and  79.712  visualizations  on  LinkedIn  at
https://www.linkedin.com/feed/update/urn:li:activity:665
3733697633812481/)
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